abstract OBJECTIVE: To determine the incidence with which a vancomycin dosing regimen of 15 mg/kg per dose every 6 hours achieves steady-state trough concentrations of 15 to 20 mg/L in pediatric patients with complicated infections.
RESULTS:
Seventy-four patients were enrolled, mean age of 4.2 ± 3.9 years and weight of 17.0 ± 11.2 kg. Five (6.8%) patients obtained an initial trough of 15 to 20 mg/L. Patients between 1.0 and 5.9 years of age were signifi cantly less likely to achieve an initial trough of 15 to 20 mg/L compared with other age groups evaluated (P = .041). Thirty-four patients with initial subtherapeutic troughs received a dose adjustment and a follow-up vancomycin trough. Of these patients, 15 (44.1%) achieved a trough between 15 and 20 mg/L. The median dose for patients achieving a therapeutic trough at any point during the study was 80 mg/kg per day.
CONCLUSIONS:
A vancomycin dosing regimen of 15 mg/kg per dose every 6 hours is not likely to achieve a trough concentration of 15 to 20 mg/L in pediatric patients with complicated infections. An initial regimen of 80 mg/kg per day for these patients may be more likely to result in therapeutic steadystate concentrations of vancomycin.
An Evaluation of Vancomycin Dosing for Complicated Infections in Pediatric Patients
Vancomycin is a glycopeptide antibiotic fi rst introduced into clinical practice during the 1950s with excellent antimicrobial activity against gram-positive microorganisms, particularly methicillin-resistant Staphylococcus aureus (MRSA). 1 The pharmacokinetics of vancomycin can vary greatly among age groups, and pediatric patients generally show an increased clearance of the drug compared with adults. 2 Traditionally, serum drug concentrations have been measured to assess for drug effi cacy and toxicity, [1] [2] [3] [4] although this has recently been a topic of great controversy in the medical literature. In response to this controversy, new recommendations for the monitoring of vancomycin were released in 2009. 5 Although specifi c to adult patients, the theories and rationales behind these new recommendations can be applied to pediatric patients (Table 1) . In 2011, the Infectious Diseases Society of America reaffi rmed these guidelines but noted that additional studies are needed for pediatric patients. 6 Pediatric clinicians currently face diffi culties with appropriate vancomycin dosing to achieve appropriate trough concentrations, particularly for the treatment of complicated infections in which a trough of 15 to 20 mg/L is recommended. Over the past 60 years, recommendations for vancomycin dosing in pediatrics have varied from 40 mg/kg per day up to 60 mg/kg per day divided every 6 to 8 hours, [7] [8] [9] [10] [11] [12] [13] [14] [15] with the Infectious Diseases Society of America recommending 15 mg/kg per dose given every 6 hours for invasive MRSA. 6 Lexi-Comp's Pediatric Dosage Handbook, a common pediatric dosing reference, recommends 60 mg/kg per day as the upper end of the starting dose for vancomycin in pediatric patients. 16 However, there is limited evidence to suggest that this dose results in the recommended steadystate trough concentrations of 15 to 20 mg/L. Based on the existing literature, our institution reached a consensus to use a vancomycin dosing regimen of 15 mg/kg per dose every 6 hours for our pediatric patient population.
We performed a retrospective chart review to determine the incidence with which this vancomycin dosing regimen achieves steady-state trough concentrations of 15 to 20 mg/L.
MATERIALS AND METHODS
Our institution is a 105-bed children's hospital connected to a 361-bed nonprofi t, adult teaching hospital. This study was a retrospective chart review of patients admitted to the children's hospital between July 1, 2009, and June 30, 2011, and was approved by the institutional review board. Inclusion criteria included the following: age 1 month to 18 years; at least 1 steadystate vancomycin trough obtained; received an initial vancomycin dose of 15 mg/kg per dose intravenously every 6 hours; and diagnosed with a complicated infection (meningitis, pneumonia, osteomyelitis, bacteremia/ sepsis, or endocarditis). Our institution defi nes all pneumonias as complicated because of the diffi culty of vancomycin penetration into the lungs, as well as the increasing incidence of communityassociated pneumonia caused by MRSA. Exclusion criteria included the following: age <1 month or >18 years; weight >50 kg; admission to the newborn nursery or NICU; receiving vancomycin therapy as an outpatient before admission; evidence of acute kidney injury or renal failure; diagnosis of cystic fi brosis; and diagnosis of an underlying oncology disorder or other disorder that would have affected normal pharmacokinetic parameters. To ensure that vancomycin steady-state concentrations were reached, the policy of our institution is to obtain initial troughs no earlier than just before the fi fth vancomycin dose. Peak concentrations were not monitored. Our primary outcome was the incidence with which vancomycin doses of 15mg/kg given every 6 hours achieves a steadystate vancomycin trough of 15 to 
Statistical Analyses
The primary outcome was evaluated using descriptive statistics. A 1-way analysis of variance was used to compare mean trough concentrations among patients based on age.
A Mann-Whitney rank sum test was used to compare fi nal vancomycin doses between patients who achieved goal troughs at any time during the study and those who did not.
RESULTS
A total of 125 patients were identifi ed as having a complicated infection. Seven patients were excluded from the study: 2 due to preexisting renal dysfunction, 1 for receipt of hemodialysis, and 4 due to initially receiving a dosing regimen different than 15 mg/kg per dose every 6 hours. Steady-state trough concentrations were obtained for a total of 74 patients ( (Fig 1) .
Mean initial vancomycin troughs were signifi cantly different among age groups (P = .041) ( Table 3) . Of all age groups evaluated, patients who were ≥1 and <6 years of age had the lowest mean initial vancomycin trough. 
DISCUSSION
Because of the currently limited amount of data, vancomycin dosing and monitoring is an important topic to address for pediatric patients. Based on the results from our study, a dosing regimen of 60 mg/kg per day is not likely to achieve a trough concentration of 15 to 20 mg/L. In fact, exactly half of All values presented as mean ± SD or n (%). SUN, serum urea nitrogen. the patients receiving this dosage regimen did not even achieve troughs ≥10 mg/L. A number of pediatric studies have been published that question the utility of the traditional pediatric dosing of 40 mg/kg per day. [7] [8] [9] [10] [11] [12] These studies generally found that 60 mg/kg per day was necessary to achieve trough concentrations of 5 to 15 mg/L, which is not consistent with current recommendations of maintaining trough concentrations at least >10 mg/L. None of these studies focused specifically on the dosing needed to obtain troughs of 15 to 20 mg/L. Madigan et al 18 published a study in 2013 on the effects of age and weight on vancomycin trough concentrations in pediatric patients. The mean vancomycin trough concentration in all patients who received 60 mg/kg per day (15 mg/kg per dose every 6 hours) was 10.7 mg/L. When stratifi ed according to age, only 16.7% of patients between the ages of 2 and 5 years achieved a therapeutic trough, defi ned as a concentration of 10 to 20 mg/L; this incidence was signifi cantly less than other age groups in the study. A previous study by Gordon et al 19 reported that children younger than 6 years had lower trough concentrations than older patients receiving the same vancomycin dose and interval. Both of these studies support our fi nding that patients between 1 and ∼6 years of age were less likely to achieve an initial therapeutic trough than patients in other age categories.
Cies and Shankar 20 performed a study in PICU patients to examine the incidence of nephrotoxicity in patients with trough concentrations of 15 to 20 mg/L compared with patients with trough concentrations <15 mg/L. Nephrotoxicity was defi ned as an absolute increase in serum creatinine of 0.3 mg/dL or a 50% increase in serum creatinine from the baseline value. There was no signifi cant difference in the incidence of nephrotoxicity between the 2 groups, suggesting that higher vancomycin trough concentrations are not associated with an increase in nephrotoxicity. In our study, no patients experienced vancomycininduced nephrotoxicity by using this defi nition, consistent with the Cies and Shankar 20 results. Although this study was not specifi cally designed to assess dosing, the authors reported that the mean dosage for patients in the hightrough cohort was 63.5 ± 17.3 mg/kg per day. However, one-third of these patients received a vancomycin dosing frequency of every 4 hours, which would signifi cantly affect vancomycin trough concentrations and potentially explain why this dose resulted in therapeutic drug concentrations.
Our study does have a number of important limitations. First, it is a retrospective analysis with limitations inherent to its study design. In addition, our sample size was small, with only 74 patients meeting inclusion criteria. Although we were able to determine that 15 mg/kg per dose given every 6 hours is not adequate to achieve troughs of 15 to 20 mg/L, our small sample size, retrospective design, and low number of repeat troughs obtained due to drug discontinuation limited our ability to determine what dosing regimen would consistently achieve target trough concentrations. The low number of repeat troughs may call into question the utility of having obtained the initial troughs to begin with, as the drug was often discontinued early into therapy.
Based on the median dose for patients who did achieve a therapeutic trough at any point in the study, it appears that a better starting regimen for pediatric patients with complicated infections would likely be ∼80 mg/kg per day. This is supported by the predictive equation fi ndings from Eiland et al, 17 but further studies are needed to confi rm these results. In addition, we noted 21 A second study showed that vancomycin troughs of 7 to 10 mg/L are likely predictive of AUC:MIC >400 when using a dosing regimen of 15 mg/kg per dose every 6 hours. 22 Based on this modeling, it may not be necessary to achieve troughs of 15 to 20 mg/L to achieve an AUC:MIC >400 in pediatric patients. However, it is essential to note that both of these pharmacokinetic modeling studies used MRSA isolates with an MIC of 1 mg/L. For isolates with a higher MIC, higher trough concentrations would be required. Therefore, these studies do not negate the importance of achieving higher trough concentrations in some patients.
CONCLUSIONS
Pediatric patients with complicated infections are not likely to achieve trough concentrations of 15 to 20 mg/L with a dosing regimen of 15 mg/kg per dose every 6 hours (60 mg/kg per day). Furthermore, this dosing regimen often does not produce troughs >10 mg/L. Patients between the ages of 1.0 and 5.9 years are at particular risk for not achieving therapeutic troughs with this dosing regimen. We suggest that patients requiring trough concentrations of 15 to 20 mg/L be started at a higher initial dose than 60 mg/kg per day. Based on the results from our study, a starting regimen of approximately 80 mg/kg per day is suggested to better achieve higher troughs, but this must be further evaluated. Higher trough concentrations do not appear to be associated with increased rates of nephrotoxicity, but this again should be further evaluated in a prospective manner.
